An amendment that would direct the Senate to prevent the repeal of prescription drug reforms that lower out-of-pocket costs for seniors and families.
Prevent repeal of prescription drug reforms that lower out-of-pocket costs for seniors and families.
Occurrences
Evidence
unverified · Source version 25555 · locator unknown
Campaign page states Alsobrooks supports the Inflation Reduction Act, which enables Medicare to negotiate certain prescription drug prices and cap insulin costs, and says she supports extending Medicare negotiation and capping drug price increases for seniors at inflation.
unverified · Source version 25556 · locator unknown
Sen. Alsobrooks submitted SA 1014, a deficit-neutral reserve fund for legislation relating to reducing health care prices, including preventing repeal of drug-pricing reform provisions or increasing costs for American families; the amendment was ordered to lie on the table.
unverified · Source version 25557 · locator unknown
On passage of H.R. 1 as amended, the Senate vote result was Bill Passed, 50 yeas to 50 nays with the Vice President voting yea; Alsobrooks (D-MD) voted Nay.
unverified · Source version 25558 · locator unknown
CRS explains that section 71203 of P.L. 119-21 expands the orphan drug exclusion to exclude from Medicare Drug Price Negotiation Program eligibility drugs designated for one or more rare diseases or conditions, effective for the third round of negotiations starting January 1, 2028.
unverified · Source version 1303 · locator unknown
SA 5212 by Ms. Alsobrooks was titled a deficit-neutral reserve fund relating to preventing repeal of prescription drug reforms that lower out-of-pocket costs for seniors and families; it was ordered to lie on the table.
unverified · Source version 25559 · locator unknown
CMS said the 2026 Part D redesign implements Inflation Reduction Act changes, including a $2,100 annual out-of-pocket threshold and changes accounting for negotiated prices taking effect for selected drugs in 2026.
verified · Source version 86702 · locator 11737
The file below contains the list of National Drug Codes (NDC) associated with the selected drug list, which represents the NDCs for which any negotiated maximum fair price would apply consistent with CMS guidance.
unverified · Source version 86702 · locator unknown
CMS announced on March 13, 2026 that the drug companies that manufacture all 15 drugs payable under Medicare Part B and/or covered under Medicare Part D selected for the third cycle of negotiation have chosen to participate in the Negotiation Program.
unverified · Source version 86704 · locator unknown
Sections 11001 and 11002 of IRA establish the Medicare Drug Price Negotiation Program (hereinafter the ``Negotiation Program'') to negotiate maximum fair prices (MFPs)
unverified · Source version 86704 · locator unknown
Section 71203 of the Working Families Tax Cuts Act expanded protections for certain orphan drugs in section 1192(e) of the Act.
unverified · Source version 86706 · locator unknown
SEC. 71203. EXPANDING AND CLARIFYING THE EXCLUSION FOR ORPHAN DRUGS UNDER THE DRUG PRICE NEGOTIATION PROGRAM.
Assessments
The verified commitment describes an amendment aimed at preventing repeal of prescription drug reforms, but the only verified outcome passage merely shows CMS was still maintaining selected-drug NDCs for negotiated maximum fair prices. That supports that some negotiation structure remained active, but it does not prove Alsobrooks materially caused preservation of the reforms or that her amendment was enacted. Because delivery or partial credit requires verified evidence of material candidate contribution, the outcome remains unresolved.
Alsobrooks took concrete same-term action to preserve IRA prescription drug reforms, including filing amendments directly framed around preventing repeal and voting against H.R. 1. The core Medicare Part D redesign and drug negotiation reforms remained in effect for 2026, so the repeal she opposed did not occur in full. However, P.L. 119-21 limited the negotiation program for certain orphan drugs, meaning the broader promise to protect reforms that lower out-of-pocket costs was only partly achieved rather than fully delivered.